Holen Sie sich die Stockscreener-App
1.54
3.36%
0.05
Vorhandelsmarkt:
1.55
0.01
+0.65%
Schlusskurs vom Vortag:
$1.49
Offen:
$1.5
24-Stunden-Volumen:
1.69M
Relative Volume:
1.07
Marktkapitalisierung:
$82.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-59.69M
KGV:
-1.1079
EPS:
-1.39
Netto-Cashflow:
$-46.54M
1W Leistung:
+4.05%
1M Leistung:
-8.88%
6M Leistung:
-22.61%
1J Leistung:
+1.32%
1-Tages-Spanne:
$1.49
$1.59
1-Wochen-Bereich:
$1.4447
$1.73
52-Wochen-Spanne:
$0.6254
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Firmenname
Milestone Pharmaceuticals Inc
Sektor
Branche
Telefon
(514) 336-0444
Adresse
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Vergleichen Sie MIST mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.54 | 125.75M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-06-20 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-07-24 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-25 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-03-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-03 | Eingeleitet | Cowen | Outperform |
| 2019-06-03 | Eingeleitet | Jefferies | Buy |
| 2019-06-03 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Milestone Pharmaceuticals Inc Aktie (MIST) Neueste Nachrichten
What analysts say about Milestone Pharmaceuticals Inc. stockConsistently superior profits - Autocar Professional
What drives Milestone Pharmaceuticals Inc. stock priceFree Bull & Bear Market Updates - Autocar Professional
Is Milestone Pharmaceuticals Inc. a good long term investmentDynamic portfolio growth - Autocar Professional
Milestone Pharmaceuticals Inc. Stock Analysis and ForecastBreakout stock performance - Autocar Professional
Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution (MIST) - Seeking Alpha
Piper Sandler Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Cuts Target Price to $4 - 富途牛牛
HC Wainwright Has Positive Estimate for MIST Q3 Earnings - Defense World
Milestone Pharmaceuticals plunges after pricing $52.5M offering - MSN
What makes Milestone Pharmaceuticals Inc. stock price move sharplyTrade Ready Signal - Newser
Why Milestone Pharmaceuticals Inc. stock attracts strong analyst attention10x Potential Stocks - Newser
How Milestone Pharmaceuticals Inc. stock performs during market volatilityPrecision Entry Strategy - Newser
Retail investors who have a significant stake must be disappointed along with institutions after Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) market cap dropped by US$9.0m - simplywall.st
Milestone Pharmaceuticals shares fall 7.37% intraday after FDA acceptance of CARDAMYST Nasal Spray response. - AInvest
Milestone Pharmaceuticals Announces Public Offering for $48.7M - TipRanks
MIST SEC FilingsMilestone Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Milestone Pharmaceuticals Initiates Capital Raise Through Securities Offering - AInvest
CARDAMYST's Regulatory Odyssey Nears Finish Line: Why Milestone Pharmaceuticals is Poised for Liftoff by Q4 2025 - AInvest
Milestone Pharma's $52.5M Warrant Offering: Betting on FDA Approval and PSVT's Untapped Market - AInvest
Milestone Pharmaceuticals' $52.5M Offering: A Risky Gamble or Strategic Lifeline? - AInvest
Milestone Pharmaceuticals (MIST) Announces $52.5M Public Offerin - GuruFocus
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge - Benzinga
Why Is Milestone Pharmaceuticals Stock Plunging On Friday? - Benzinga
Milestone Pharmaceuticals (MIST) Shares Plummet After $52.5 Mill - GuruFocus
Milestone Pharmaceuticals announces pricing of $52.5 million public offering - MarketScreener
Milestone Pharmaceuticals prices $52.5 million public offering - Investing.com India
Milestone Pharmaceuticals prices $52.5 million public offering By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Pub - GuruFocus
Milestone Pharmaceuticals Plummets 39%—What’s Behind the Freefall? - AInvest
Milestone Pharmaceuticals Shares Drop Sharply After Public Offering Announcement - MSN
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants - TradingView
Milestone Pharmaceuticals Secures $52.5M Funding to Advance Breakthrough PSVT Heart Treatment - Stock Titan
Navigating the Dilution Crossroads: Milestone Pharmaceuticals' Financing – Gateway or Value Trap? - AInvest
Milestone Pharmaceuticals Poised to Break Through with CARDAMYST: A Strategic Play Ahead of FDA's December Decision - AInvest
Milestone Pharmaceuticals stock plunges on public offering announcement By Investing.com - Investing.com Nigeria
Milestone Pharmaceuticals announces proposed public offering - MarketScreener
Finanzdaten der Milestone Pharmaceuticals Inc-Aktie (MIST)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):